Ribozyme Therapeutics  by Kashani-Sabet, Mohammed
Ribozyme Therapeutics
Mohammed Kashani-Sabet
Auerback Melanoma Research Laboratory, Cutaneous Oncology Program, UCSF Cancer Center, and Department of Dermatology, University of
California San Francisco, San Francisco, California, USA
Since their initial discovery, ribozymes have shown
great promise not just as a tool in the manipulation of
gene expression, but also as a novel therapeutic agent.
This review discusses the promises and pitfalls of ribo-
zyme technology, with a special emphasis on cancer-
related applications, though relevance to skin disease
will also be discussed. Key words: Catalytic RNA/gene de-
livery/cancer gene therapy. JID Symposium Proceedings
7:76 ^78, 2002
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ibozymes (or RNA enzymes) are catalytic RNA
capable of cleaving target RNA molecules in a se-
quence-speci¢c manner. Ribozymes were discov-
ered in the early 1980s in two di¡erent systems,
Tetrahymena thermophila (Zaug and Cech, 1986)
and ribonuclease P of Escherichia coli (Guerrier-Takada et al, 1983),
as self-cleaving molecules, lending support to the notion that cur-
rent biologic systems evolved from a so-called ‘‘RNA world’’.
Subsequently, other catalytic RNA were discovered in plant
viruses that could be used to cleave a target RNA in trans. These
included the hammerhead ribozyme, identi¢ed in the virusoid
from lucerne transient streak virus (Forster and Symonds, 1987),
the hairpin ribozyme, identi¢ed from the ‘‘minus’’ strand of satel-
lite RNA of tobacco ringspot virus (Hampel et al, 1990), and the
hepatitis delta ribozyme (Branch and Robertson, 1991). This re-
view will focus primarily on the hammerhead ribozyme, which
has been most extensively characterized in gene therapy applica-
tions. The reader is referred to several reviews focusing on di¡er-
ent aspects of ribozyme chemistry or biology (James and Gibson,
1998; Scanlon and Kashani-Sabet, 1998a; 1998b).
Two motifs comprise the hammerhead ribozyme: a catalytic
core, which is responsible for the cleavage reaction, and three hy-
bridizing helices, two of which £ank the catalytic core and bind
the target RNA in antisense fashion using Watson^Crick base
pairing (Fig 1). In general, hammerhead ribozymes recognize tar-
get RNA containing XUN sequences, where X is any base and
N is A, C, or U. Favored target sites are those containing GUC,
GUA, GUU, CUC, and UUC sequences. The primary mechan-
ism of action of hammerhead ribozymes in suppressing target
gene expression is cleavage of the target RNA immediately 30 to
the XUN sequence. This action yields two shorter RNA species
that, being devoid of stabilizing sequences, are rapidly degraded,
resulting in progressively decreased protein synthesis. Having
cleaved one target RNA molecule, the ribozyme dissociates and
can target a second molecule and enter into the next round of
cleavage reaction, thus acting in a catalytic manner in trans (Uh-
lenbeck, 1987). In addition to this dominant mechanism of action,
ribozymes have the potential advantage of e¡ecting antisense-
based suppression as well. Ribozymes generated by the endogen-
ous transcriptional apparatus (such as when delivered by plasmids
or viruses) can block translational machinery through activation
of Rnase recognizing double-stranded RNA. Ribozymes deliv-
ered as single-stranded modi¢ed oligomers (such as those using
phosphorothioate oligodeoxynucleotides) can also activate Rnase
H, which recognizes DNA^RNA pairings.
ISSUES IN RIBOZYME DESIGN AND DELIVERY
One of the central issues in ensuring the success of a ribozyme-
based experiment is the proper selection of the target gene and
the optimal design of the ribozyme. The selected target gene
is usually prominently involved in producing the phenotype
of interest; however, a major issue that must be considered in
the design of a ribozyme experiment includes knowledge of the
half-life of the target message and protein. The more stable the
target gene and protein, the more prolonged inhibition may be
necessary to produce the desired suppression of expression and
change in biologic phenotype. Thus, many target genes may not
be susceptible to transient transfections and may require pro-
longed expression, which in in vitro studies entails the use of
stable transformants expressing the ribozyme under antibiotic se-
lection. Until recently, the requirement for high levels of ribo-
zyme expression to produce sustained inhibition was a major
obstacle for in vivo studies requiring repeated administrations of
the ribozyme.
The selection of the speci¢c sequence within the target gene is
another issue that deserves attention in the design of a ribozyme.
In short, this di¡ers from target to target and must be tested with
the design of each new molecule, as ribozymes have been success-
fully designed to target the 50 end of the mRNA, the 30 untrans-
lated region, or regions in between. A major determinant of an
active ribozyme is accessibility of the target RNA, which is
greatly reduced by double-stranded regions of folded single-
stranded RNA and sites of interaction with RNA-binding pro-
teins. Potential strategies used to circumvent these obstacles, such
as RNA folding predictions or screening of ribozymes using
in vitro cleavage of target RNA, are not always successful. There-
fore, in a given experiment, it is imperative that several ribozymes
targeting the RNA of interest be designed and tested.
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The next major issue in the testing of a ribozyme is the
selection of the oligomer’s nucleotide backbone. This frequently
is intertwined with the delivery agent to be used. If the ribozyme
RNA is the intended active agent, then it must be cloned into an
expression plasmid and transcribed intracellularly, as ribozymes
delivered in their RNA form are susceptible to degradation by
serum nucleases. This expression cassette can either be delivered
by itself (naked DNA), which is inherently ine⁄cient, or com-
plexed with a delivery agent, frequently cationic liposomes. Al-
ternatively, ribozymes can be delivered and expressed using
viruses. Finally, if the ribozyme oligonucleotide is to be delivered
to the cell, tissue, or animal exogenously, it needs to be modi¢ed
to become more stable and nuclease resistant.These modi¢cations
have typically included the use of chimeric DNA^RNA hybrid
molecules given that certain bases within the ribozyme need to
have a ribonucleotide backbone, whereas the rest can have a
deoxynucleotide, resulting in increased stability (Taylor et al,
1992). Second, modi¢cations of the phosphodiester backbone
have also resulted in improved nuclease resistance.The most com-
monly used antisense oligomer is the phosphorothioate oligo-
deoxynucleotide (ODN), in which a single sulfur substitutes
for oxygen at a nonbridging position at each phosphorus atom
(Flanagan, 1998). Despite encouraging initial results using
such constructs, signi¢cant obstacles remain in the use of
phosphorothioate ODN that cast doubt on the mechanism of in-
hibition of gene expression. To begin with, ODN with four con-
secutive guanine residues have been shown to display signi¢cant
protein-binding properties (Krieg et al, 1995). Speci¢cally, phos-
phorothioate ODN have been shown to have signi¢cant interac-
tions with heparin-binding proteins, including growth factor
receptors (Guvakova et al, 1995). Moreover, phosphorothioate
ODN have been shown to produce signi¢cant nonsequence-spe-
ci¢c e¡ects in biologic systems, including signi¢cant antitumor
e¡ects (Burgess et al, 1995), leading some experts to question
whether absolute sequence speci¢city is achievable with such
constructs (Stein, 2001). Therefore, for in vivo gene therapy appli-
cations, expression of the ribozyme by plasmid DNA or viral
vector still represents the best tested method.
Finally, important obstacles exist in the delivery of antisense or
ribozyme ODN to cells. Given the net negative charge of DNA,
these molecules di¡use poorly across lipophilic cell membranes,
thereby prompting some investigators to complex themwith po-
sitively charged liposomes. Recently, the cell surface receptor for
ODN was identi¢ed to be Mac-1 or CD11b/CD18, a member of
the integrin family (Benimetskaya et al, 1997). Upon binding to
Mac-1 or following endocytosis, ODN are internalized and
shuttled to the endosomal compartment, where they are apt to
undergo enzymatic degradation. One strategy to overcome some
of these delivery problems is tissue- or cell-speci¢c targeting,
such as the use of immunoliposomes targeting the ganglioside
GD2 to deliver antisense c-myb preferentially to neuroblastoma
cells (Pagnan et al, 2000).
APPLICATIONS
The initial demonstration of trans-acting catalytic activity of the
hammerhead ribozyme (Haselo¡ and Gerlach, 1988) paved the
way for use of ribozymes as tools to manipulate the expression
of potentially any gene. Shortly thereafter, the ¢rst application
of hammerhead ribozymes as a novel therapeutic agent was
examined in the setting of human immunode¢ciency virus
(HIV) infection (Sarver et al, 1990). Subsequently, the ¢rst use of
ribozymes in the realm of human cancer targeted the c-fos onco-
gene as a strategy to reverse resistance to the chemotherapeutic
agent cisplatin (Scanlon et al, 1991).
Ribozymes have been utilized in several settings with poten-
tial relevance to dermatologic diseases. Ample evidence exists to
support the use of ribozyme-based technology in the validation
of target genes that may play a role in a particular biologic process
or that produce a particular phenotype in vitro or in vivo. As indi-
cated previously, ribozymes were used to assign a role for the c-fos
oncogene in the multidrug resistant phenotype (Scanlon et al,
1991, 1994). More recently, our group has used in vivo, plasmid-
based ribozyme targeting to identify pro-metastatic function for
the transcriptional activator nuclear factor kB (NFkB) in mela-
noma (Kashani-Sabet et al, 2002) and to dissect out the roles of
genes operating in the NFkB signaling pathway that function to
produce the metastatic phenotype. These studies suggest the en-
ormous potential utility of ribozymes for functional genomics
applications given the completion of the human genome project.
Recently, an in vitro reverse genomics approach using a random
ribozyme library was utilized to show that telomerase may sup-
press cellular transformation (Li et al, 2000).
In addition to studies of gene function, ribozymes have been
utilized for their potential therapeutic applications, largely in the
realm of HIV and cancer. Salient examples of therapeutic uses of
ribozymes in preclinical models include adenovirus-mediated
antioncogene ribozymes targeting H-ras and HER-2/neu in the
therapy of bladder and breast cancer (Irie et al, 1999; Suzuki et al,
2000). More recently, continuous infusions of an RNA-DNA
chimeric ribozyme phosphorothioate ODN targeting the vascu-
lar endothelial growth factor receptor £t-1 were used to produce
antimetastatic and antiangiogenic e¡ects in murine models, re-
sulting in ongoing phase II studies of this agent in several ad-
vanced malignancies (Pavco et al, 2000). Moreover, a hairpin
ribozyme is being tested in clinical trials as a therapeutic agent
of HIV infection.
The major impediment to the initiation of additional clinical
trials using ribozyme technology is the lack of a vector that pro-
duces high levels of the desired ribozyme for prolonged periods,
and that can be reinjected repeatedly into the host. In this regard,
the recent development of a novel plasmid vector containing ele-
ments from the Epstein^Barr virus (EBV) genome may possibly
circumvent a number of these limitations (Tu et al, 2000). The
plasmid vector system includes both the Epstein^Barr nuclear
antigen-1 and family of repeat. Systemic administration of this
nonreplicating vector system signi¢cantly improved the thera-
peutic e⁄cacy of the granulocyte colony-stimulating factor gene,
such that white blood counts were elevated for at least 2 mo fol-
lowing a single intravenous injection (Tu et al, 2000). An addi-
tional intriguing feature of this vector system is that it could be
readministered repeated times into immunocompetent mice
without loss of transfection e⁄ciency.
Figure1. The hammerhead ribozyme relative to its target RNA
substrate. Conserved sequences as well as the cleavage site are speci¢ed.
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Our recent studies using this plasmid vector complexed with
cationic liposomes have shown that ribozyme-based targeting of
the NFkB pathway resulted in profound anti-invasive and anti-
metastatic e¡ects against B16-F10 murine melanoma (Kashani-
Sabet et al, 2002). A single injection of cationic liposome: DNA
complexes expressing ribozymes targeting the p65 or p50 subu-
nits of NFkB resulted in 40%^60% reductions in B16 lung me-
tastases. Moreover, delivery of ribozymes targeting the NFkB-
regulated genes integrin b3 and platelet-endothelial cell adhesion
molecule-1 also resulted in signi¢cant antimetastatic e¡ects, sug-
gesting that this ligand^receptor pair may mediate the pro-meta-
static e¡ects of NFkB (Kashani-Sabet et al, 2002). These results
strongly suggest the utility of systemic plasmid-based delivery
of ribozymes for the treatment of metastatic melanoma. More-
over, they suggest the preclinical therapeutic e⁄cacy of plasmid-
based ribozymes to treat and/or prevent melanoma metastasis.
Table I summarizes some of the other target genes for which ri-
bozymes have been used in preclinical studies.
For the application of ribozyme technology to skin diseases,
further developments in gene transfer to the skin will be required
(reviewed by Vogel in this series); however, ribozyme-based tar-
geting for the treatment of nonmalignant diseases in the skin is
especially attractive given the profound e¡ects that targeted sup-
pression of a single gene may have in the control of in£ammatory
diseases or genodermatoses. One of the challenges in using ribo-
zyme-based approaches for epithelial disorders is the di⁄culty in
achieving and maintaining high-level transfection e⁄ciency in
epidermal stem cells in whom transgene expression is frequently
lost upon di¡erentiation. In this regard, it would be intriguing to
examine the cutaneous delivery of plasmid-based ribozymes
using the long-expressing EBV-based vector discussed above in
an attempt to circumvent this limitation. Finally, the preliminary
in vitro demonstrations of repair of gene mutations using ribo-
zymes (Watanabe and Sullenger, 2000) has an obvious appeal
in the treatment of skin disorders characterized by a dominant
mutant allele.
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Table I. Ribozyme-based therapy in preclinical models of human cancer
Target gene Phenotype Reference
H-ras Reduced tumor cell growth, tumorigenicity, invasiveness Irie et al (1999); Kashani-Sabet et al (1994); Ohta et al (1996)
HER-2/neu Reduced tumor cell growth, tumorigenicity Suzuki et al (2000)
fos Reduced drug resistance Scanlon et al (1991, 1994)
NFkB Reduced invasion and metastasis Kashani-Sabet et al (2002)
Flt-1 Reduced angiogenesis and metastasis Pavco et al (2000)
Bcr-abl Reduced tumor cell growth in vitro Snyder et al (1993)
Pleiotrophin Reduced angiogenesis and metastasis Czubayko et al (1996)
Epidermal growth factor receptor Reduced growth of xenograft tumors Yamazaki et al (1998)
Telomerase Increased doubling time Folini et al (2000)
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